Clinicopathological Significance of BRAF V600E Mutation in Egyptian Colorectal Cancer Patients | ||||
| The Medical Journal of Cairo University | ||||
| Article 2, Volume 88, June, June 2020, Page 991-997 PDF (606.43 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2020.110833 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| MONA A. KORA, M.Sc.; NANSY Y. ASAAD, M.D.; HALA S. EL-REBEY, M.D.; RANIA A. HASSANIN, M.D.; ALSHIMAA M. ALHANAFY, M.D. | ||||
| The Departments of Pathology* and Oncology and Nuclear Medicine**, Faculties of Medicine, Menoufia University | ||||
| Abstract | ||||
| Abstract Background: In Egypt, there is a rapid increase in Color-ectal Cancer (CRC) incidence with more aggressive course and younger age at presentation compared to western patients. Aim of Study: This study aimed to examine BRAF V600E mutation in Egyptian CRC patients. Material and Methods: This study is done by collaboration between Pathology and Clinical Oncology & Nuclear Medicine Departments, Faculty of Medicine, Menoufia University between January 2015 and August 2019 in which 81 CRC patients were studied. Expression of BRAF V600E protein was evaluated by immunohistochemistry. The results of the studied marker were correlated with different clinicopatho-logical parameters and survival data. Results: The frequency of BRAF V600E mutation was 51.9%. There was no statistical difference between different studied clinicopathological parameters including sidedness and BRAF V600E mutation. Regarding survival during this follow-up duration, no significant statistical differences were detected. Conclusion: In Egyptian CRC patients, BRAF V600E protein expression had no correlation with CRC prognosis. However, validation of our results in a larger sample size is necessary. | ||||
| Keywords | ||||
| Egyptian colorectal cancer; BRAF V600E; Protein expression; Prognosis | ||||
|
Statistics Article View: 258 PDF Download: 261 |
||||
